Andrew Blitzer1. 1. College of Physicians and Surgeons, Columbia University, New York Center for Voice and Swallowing Disorders, New York, NY 10019, USA. AB1136@aol.com
Abstract
OBJECTIVE: The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles. METHODS: Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response. RESULTS: The conversion factor was found to be 52.3 U:1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth. CONCLUSION: This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia.
OBJECTIVE: The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles. METHODS: Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response. RESULTS: The conversion factor was found to be 52.3 U:1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth. CONCLUSION: This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia.
Authors: Daniel Martinez-Ramirez; Juan C Giugni; Erin Hastings; Aparna Wagle Shukla; Irene A Malaty; Michael S Okun; Ramon L Rodriguez Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2014-12-15
Authors: Alberto Albanese; Giovanni Abbruzzese; Dirk Dressler; Wojciech Duzynski; Svetlana Khatkova; Maria Jose Marti; Pablo Mir; Cesare Montecucco; Elena Moro; Michaela Pinter; Maja Relja; Emmanuel Roze; Inger Marie Skogseid; Sofiya Timerbaeva; Charalampos Tzoulis Journal: J Neurol Date: 2015-04-01 Impact factor: 4.849